% | $
Quotes you view appear here for quick access.

YM BioSciences, Inc. Ordinary S Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • trader_007 trader_007 Jan 5, 2012 1:08 PM Flag

    ISI Group analyst Mark Schoenebaum

    I don't know, but, he seems to contradict himself.

    Biggest Upside for 2012
    "YMI takeout"

    Biggest Downside for 2012
    "YMI - based on its ASH poster in Dec' 11 on its myelofibrosis drug CYT387, YMI has raised hopes of being able to treat anemia in sickle cell disease and thalassemia patients. These hopes will be dashed in '12."

    I think he's full of crap and just making guesses.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • graysonbarnes Jan 5, 2012 1:22 PM Flag

      I think he is refering only to the "raised hopes" of CYT 387 being able to alleviate anemia related to sickle cell. I don't think he's refering to the overall hopes of YM Biosciences and CYT 387 being dashed.

      • 1 Reply to graysonbarnes
      • Their has been some chatter about the role of JAK2 in sickle cell disease as well as thalassemia. But that's about it. Their are no studies, other than mouse studies, that I know of. Obviously this would be beyond huge as these are among the most commonly inherited diseases in the world. They know that JAK2 is highly expressed in Cooley's anemia. This has no bearing on the stock at this time and I don't know why he'ld bring it up. Seems to me he's just throwing out wild predictions.